{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021505","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.335279+00:00","generated_at":"2026-06-15T02:39:29.423147+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IN8bio Q1 net loss $7.5M, cash $10.9M; INB-100 achieves 100% CR in leukemia trial","bullets":["Q1 net loss $7.5M ($0.30/sh); cash $10.9M at Mar 31; raised $9.9M via ATM after quarter end.","INB-100 Phase 1: 100% complete remissions in 7 evaluable leukemia patients; all alive; selected RP2D.","FDA orphan drug designation for INB-400 and INB-410 for malignant gliomas, including GBM.","INB-200 Phase 1 data selected for oral abstract at ASCO 2023; new preclinical data in ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021505","json":"https://secwatch.observer/filing/0000950170-23-021505.json","markdown":"https://secwatch.observer/filing/0000950170-23-021505.md","text":"https://secwatch.observer/filing/0000950170-23-021505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/0000950170-23-021505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/inab-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:39:29.423147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0189648711e8ab9d5f0546f2ea60042981563d6","claim":"IN8BIO, INC. reported first quarter ended March 31, 2023 results: net income $7.5 million, EPS $0.30 per basic and diluted common share.","evidence_excerpt":"The Company reported a net loss of $7.5 million, or $0.30 per basic and diluted common share, for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/0000950170-23-021505-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$7.5 million"},{"label":"EPS","value":"$0.30 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}